SE452766B - Piperazinderivat, deras framstellning och farmaceutiska kompositioner innehallande dessa - Google Patents
Piperazinderivat, deras framstellning och farmaceutiska kompositioner innehallande dessaInfo
- Publication number
- SE452766B SE452766B SE8302979A SE8302979A SE452766B SE 452766 B SE452766 B SE 452766B SE 8302979 A SE8302979 A SE 8302979A SE 8302979 A SE8302979 A SE 8302979A SE 452766 B SE452766 B SE 452766B
- Authority
- SE
- Sweden
- Prior art keywords
- formula
- compound
- compounds
- meanings given
- hydrogen
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical class C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title description 3
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 74
- 238000000034 method Methods 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 238000007363 ring formation reaction Methods 0.000 claims description 5
- 125000006243 carbonyl protecting group Chemical group 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 150000001721 carbon Chemical group 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000012458 free base Substances 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 239000008024 pharmaceutical diluent Substances 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- -1 2-amino-3-nitro-pyridin-6-yl Chemical group 0.000 description 8
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000002904 solvent Substances 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 229950001675 spiperone Drugs 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 229940125890 compound Ia Drugs 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 229920000137 polyphosphoric acid Polymers 0.000 description 3
- 229960001289 prazosin Drugs 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical compound [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 230000000059 bradycardiac effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 239000003176 neuroleptic agent Substances 0.000 description 2
- 230000000701 neuroleptic effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- WLDLFZGXYXOVFH-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-piperazin-1-ylbutan-1-one;dihydrochloride Chemical compound Cl.Cl.C1=CC(F)=CC=C1C(=O)CCCN1CCNCC1 WLDLFZGXYXOVFH-UHFFFAOYSA-N 0.000 description 1
- YKWBEPUOVBMENG-UHFFFAOYSA-N 2-chloro-5-nitropyridin-4-amine Chemical compound NC1=CC(Cl)=NC=C1[N+]([O-])=O YKWBEPUOVBMENG-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- DAQZLSBLEGJXDU-UHFFFAOYSA-N 4-[4-(5,6-diaminopyridin-2-yl)piperazin-1-yl]-1-(4-fluorophenyl)butan-1-one Chemical compound N1=C(N)C(N)=CC=C1N1CCN(CCCC(=O)C=2C=CC(F)=CC=2)CC1 DAQZLSBLEGJXDU-UHFFFAOYSA-N 0.000 description 1
- PTVJZEFMSLHQIO-UHFFFAOYSA-N 4-[4-(5,6-diaminopyridin-2-yl)piperazin-1-yl]-1-(4-fluorophenyl)butan-1-one ethene Chemical group C=C.N1=C(N)C(N)=CC=C1N1CCN(CCCC(=O)C=2C=CC(F)=CC=2)CC1 PTVJZEFMSLHQIO-UHFFFAOYSA-N 0.000 description 1
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
- 108091005479 5-HT2 receptors Proteins 0.000 description 1
- WERABQRUGJIMKQ-UHFFFAOYSA-N 6-chloro-3-nitropyridin-2-amine Chemical compound NC1=NC(Cl)=CC=C1[N+]([O-])=O WERABQRUGJIMKQ-UHFFFAOYSA-N 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100274389 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) chz-1 gene Proteins 0.000 description 1
- 108091002531 OF-1 protein Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- RSUVYMGADVXGOU-BUHFOSPRSA-N cinanserin Chemical compound CN(C)CCCSC1=CC=CC=C1NC(=O)\C=C\C1=CC=CC=C1 RSUVYMGADVXGOU-BUHFOSPRSA-N 0.000 description 1
- 229950001684 cinanserin Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
- 229960001999 phentolamine Drugs 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH331782 | 1982-05-28 | ||
| CH337982 | 1982-06-02 | ||
| CH448482 | 1982-07-22 | ||
| CH448582 | 1982-07-22 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE8302979D0 SE8302979D0 (sv) | 1983-05-26 |
| SE8302979L SE8302979L (sv) | 1983-11-29 |
| SE452766B true SE452766B (sv) | 1987-12-14 |
Family
ID=27428609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8302979A SE452766B (sv) | 1982-05-28 | 1983-05-26 | Piperazinderivat, deras framstellning och farmaceutiska kompositioner innehallande dessa |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US4565816A (pt) |
| AU (1) | AU573524B2 (pt) |
| CA (1) | CA1203801A (pt) |
| DE (1) | DE3318671A1 (pt) |
| DK (1) | DK237383A (pt) |
| ES (1) | ES522786A0 (pt) |
| FI (1) | FI73999C (pt) |
| FR (2) | FR2527608B1 (pt) |
| GB (1) | GB2120670B (pt) |
| HU (1) | HU191844B (pt) |
| IE (1) | IE55312B1 (pt) |
| IL (1) | IL68793A (pt) |
| NL (1) | NL8301844A (pt) |
| NZ (1) | NZ204369A (pt) |
| PH (1) | PH22871A (pt) |
| PT (1) | PT76768B (pt) |
| SE (1) | SE452766B (pt) |
| WO (1) | WO1983004254A1 (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4803203A (en) * | 1986-11-05 | 1989-02-07 | Warner-Lambert Company | Phenyl and heterocyclic piperazinyl alkoxy-benzheterocyclic compounds as antipsychotic agents |
| US5502187A (en) * | 1992-04-03 | 1996-03-26 | The Upjohn Company | Pharmaceutically active bicyclic-heterocyclic amines |
| US6432957B1 (en) * | 2001-06-29 | 2002-08-13 | Kowa Co., Ltd. | Piperazine derivative |
| GB0215293D0 (en) | 2002-07-03 | 2002-08-14 | Rega Foundation | Viral inhibitors |
| NZ595000A (en) * | 2003-12-22 | 2013-03-28 | Gilead Sciences Inc | Imidazo[4,5-c]pyridine derivative for treating viral infections |
| NZ556624A (en) * | 2004-12-21 | 2010-06-25 | Gilead Sciences Inc | 5-((3-(2,4-trifluoromethyphenyl)isoxazol-5-yl)methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine and method of antiviral treatment |
| US7582636B2 (en) * | 2005-05-26 | 2009-09-01 | Wyeth | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor |
| DE602007004220D1 (de) * | 2006-07-07 | 2010-02-25 | Leuven K U Res & Dev | Neue pyridazinverbindung und ihre verwendung |
| UA99466C2 (en) | 2007-07-06 | 2012-08-27 | Гилиад Сайенсиз, Инк. | Crystalline pyridazine compound |
| JP5960688B2 (ja) | 2010-05-17 | 2016-08-02 | インコゼン セラピューティクス プライベート リミテッド | プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物 |
| CN102952121A (zh) * | 2012-07-27 | 2013-03-06 | 北京海步国际医药科技发展有限公司 | 一种哌嗪衍生物的一种改进的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL129219C (pt) * | 1965-12-16 | |||
| GB1165283A (en) * | 1967-01-17 | 1969-09-24 | Science Union & Cie | New Purine Derivatives and processes for prepararing them |
| US4022779A (en) * | 1974-07-25 | 1977-05-10 | E. R. Squibb & Sons, Inc. | Amino derivatives of pyrido(3,4-b)pyrazine carboxylic acids and esters |
| US4082845A (en) * | 1977-04-25 | 1978-04-04 | Merck & Co., Inc. | 3-(1-Piperazinyl)-pyrido[2,3-b]pyrazines |
-
1983
- 1983-05-19 FR FR8308484A patent/FR2527608B1/fr not_active Expired
- 1983-05-20 FI FI831790A patent/FI73999C/fi not_active IP Right Cessation
- 1983-05-21 DE DE19833318671 patent/DE3318671A1/de not_active Withdrawn
- 1983-05-25 WO PCT/CH1983/000067 patent/WO1983004254A1/de not_active Ceased
- 1983-05-25 NL NL8301844A patent/NL8301844A/nl not_active Application Discontinuation
- 1983-05-25 GB GB08314456A patent/GB2120670B/en not_active Expired
- 1983-05-26 CA CA000428935A patent/CA1203801A/en not_active Expired
- 1983-05-26 SE SE8302979A patent/SE452766B/sv not_active IP Right Cessation
- 1983-05-26 PT PT76768A patent/PT76768B/pt unknown
- 1983-05-26 DK DK237383A patent/DK237383A/da not_active Application Discontinuation
- 1983-05-26 AU AU15012/83A patent/AU573524B2/en not_active Ceased
- 1983-05-26 PH PH28969A patent/PH22871A/en unknown
- 1983-05-26 IL IL68793A patent/IL68793A/xx unknown
- 1983-05-26 HU HU831873A patent/HU191844B/hu not_active IP Right Cessation
- 1983-05-26 NZ NZ204369A patent/NZ204369A/en unknown
- 1983-05-27 US US06/498,952 patent/US4565816A/en not_active Expired - Fee Related
- 1983-05-27 IE IE1263/83A patent/IE55312B1/en unknown
- 1983-05-27 ES ES522786A patent/ES522786A0/es active Granted
- 1983-09-12 FR FR8314586A patent/FR2536398B1/fr not_active Expired
-
1985
- 1985-10-04 US US06/784,832 patent/US4652565A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| PT76768A (fr) | 1983-06-01 |
| DE3318671A1 (de) | 1983-12-01 |
| DK237383A (da) | 1983-11-29 |
| FR2536398B1 (fr) | 1986-12-05 |
| ES8502988A1 (es) | 1985-02-01 |
| FI831790L (fi) | 1983-11-29 |
| PH22871A (en) | 1989-01-19 |
| FR2527608A1 (fr) | 1983-12-02 |
| IL68793A0 (en) | 1983-09-30 |
| SE8302979D0 (sv) | 1983-05-26 |
| IE831263L (en) | 1983-11-28 |
| NL8301844A (nl) | 1983-12-16 |
| SE8302979L (sv) | 1983-11-29 |
| ES522786A0 (es) | 1985-02-01 |
| US4565816A (en) | 1986-01-21 |
| GB2120670B (en) | 1985-11-27 |
| IE55312B1 (en) | 1990-08-01 |
| DK237383D0 (da) | 1983-05-26 |
| GB2120670A (en) | 1983-12-07 |
| FR2536398A1 (fr) | 1984-05-25 |
| HU191844B (en) | 1987-04-28 |
| AU1501283A (en) | 1983-12-01 |
| AU573524B2 (en) | 1988-06-16 |
| FI73999C (fi) | 1987-12-10 |
| NZ204369A (en) | 1986-09-10 |
| PT76768B (fr) | 1986-01-28 |
| WO1983004254A1 (fr) | 1983-12-08 |
| FI73999B (fi) | 1987-08-31 |
| CA1203801A (en) | 1986-04-29 |
| FR2527608B1 (fr) | 1986-10-10 |
| FI831790A0 (fi) | 1983-05-20 |
| IL68793A (en) | 1987-03-31 |
| GB8314456D0 (en) | 1983-06-29 |
| US4652565A (en) | 1987-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4086663B2 (ja) | 新規なスピロ三環式誘導体及びホスホジエステラーゼ７阻害剤としてのそれらの使用 | |
| SE453088B (sv) | 2-(4-((4,4-dialkyl-2,6-piperidindion-1-yl-)butyl)-1-piperazinyl)pyrimidiner, deras framstellning och farmaceutiska kompositioner | |
| US5246935A (en) | Piperazinyl derivatives and methods of treating central nervous system ailments relating to the 5-ht2 receptor system | |
| CA2399864A1 (en) | 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases | |
| JP2000505072A (ja) | 置換アザ―及びジアザシクロヘプタン―及び―シクロオクタン化合物及びその使用 | |
| HU190997B (en) | Process for preparing benzisothiazolyl-and benzisoxazolyl-piperazine derivatives | |
| MX2008001020A (es) | Un monohidrato de pirrolo[1-2-b]pirazol piridin quinolin substituido como inhibidor de factor de crecimiento de transformacion-beta (tgf-beta). | |
| MX2011000026A (es) | Inhibidores de proteina cinasas. | |
| EP0555478A1 (en) | Pyrimidine derivative and medicine | |
| RU2198888C2 (ru) | 3-замещенные производные 3,4,5,6,7,8-гексагидропиридо[4',3':4,5]-тиено[2,3-d]пиримидина | |
| SE452766B (sv) | Piperazinderivat, deras framstellning och farmaceutiska kompositioner innehallande dessa | |
| EP0784055A1 (en) | Pyrimidinylpyrazole derivative | |
| JP5062938B2 (ja) | セロトニン受容体及びドーパミン受容体にアフィニティーを有する新規ｎ，ｎ’−二置換ベンゾイミダゾロン誘導体 | |
| CA1209994A (en) | 2-piperazinyl-quinazoline derivatives, their production and pharmaceutical compositions containing them | |
| US5252576A (en) | 1-amino-5-halogenouracils, process for their preparation, and central nervous system depressants containing same as active ingredient | |
| KR20010101440A (ko) | 대뇌 허혈의 예방 및 치료를 위한 2-치환된1,2-벤즈이소티아졸 유도체 및 3-치환된테트라히드로피리도피리미디논 유도체의 용도 | |
| SE442511B (sv) | 2,6-bis-(aminoacylamino)-benso-/1,2-d:5,4-d'/-bistiazoler och 2-amino-6-(aminoacylamino)-benso-/1,2-d:5,4-d'/-bistiazoler samt forfarande for deras framstellning | |
| SK282424B6 (sk) | "S" a "T" kryštalické formy 1-[5-metánsulfónamidoindolyl-2- karbonyl]-4-[3-(1-metyl-etylamino)-2-pyridinyl] piperazínu | |
| SE466150B (sv) | Pilokarpinderivat, foerfarande foer framstaellning av detta och en farmaceutisk komposition | |
| GB2048256A (en) | Aminoisoquinoline derivatives and a process for the preparation thereof | |
| HK1061854B (en) | Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors | |
| JPWO1992004333A1 (ja) | ピリミジン誘導体及び医薬 | |
| MXPA99001574A (en) | Fused indolecarboxamides:dopamine receptor subtype specific ligands | |
| CZ20001436A3 (cs) | Disubstituované deriváty 1,2-benzisotiazolu a jejich použití |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 8302979-3 Effective date: 19910123 Format of ref document f/p: F |